Faeth Therapeutics (FTH) News
NASDAQ: FTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FTH news summary
We found 9 recent headlines mentioning Faeth Therapeutics (FTH): 1 in the past week and 8 in the past 30 days, most often from Nasdaq, Investor's Business Daily, Investing.com. FTH is making an outsized move today, down 9.32% at $7.88, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Faeth Therapeutics (FTH): Betting On Multi-Node Blockade To Disrupt Cancer Growth", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Faeth Therapeutics headlines
- Faeth Therapeutics (FTH): Betting On Multi-Node Blockade To Disrupt Cancer Growth(RTTNews) - Key PointsNasdaqFTH, BIO.B
- Sensei Biotherapeutics Announces Phase 2 PIK-201 Topline Results for PIKTOR in Endometrial CancerSensei Biotherapeutics, Inc. (filed under the name Faeth Therapeutics, Inc.) announced topline clinical data from its Phase 2 PIK-201 trial evaluating PIKTOR in combination with paclitaxel in…Nasdaq
- Sensei Biotherapeutics, Inc. Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 TrialSensei Biotherapeutics, Inc. (reported as Faeth Therapeutics, Inc.) today announced topline clinical data from its Phase 2 trial (FTH-PIK-201; NCT06463028; GOG-3111) of PIKTOR, an investigational…Nasdaq
- Faeth Therapeutics Plummets 45% — Here's What HappenedBiotech stock Faeth Therapeutics crashed Monday as investors questioned the effectiveness of its endometrial cancer drug. The post Faeth Therapeutics Plummets 45% — Here's What Happened appeared…Investor's Business Daily
- Faeth Therapeutics reports positive Phase 2 results for endometrial cancer drugInvesting.com
- Sensei Biotherapeutics, Inc. Reports Third Quarter 2026 Financial ResultsSensei Biotherapeutics, Inc. (operating as Faeth Therapeutics, Inc.) reported its financial results for the quarter ended September 30, 2026. The company reported cash, cash equivalents and…NasdaqFTH, LEN.B
- Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational UpdatesAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…Business Wire
- Sensei Biotherapeutics, Inc. Appoints Adam Schayowitz to Board of Directors on October 23, 2026On October 23, 2026, the Board of Directors of Faeth Therapeutics, Inc., also known as Sensei Biotherapeutics, Inc., increased the size of the Board from six to seven directors and appointed Adam…Nasdaq
- Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH(RTTNews) - The following biotech stocks reached a 52-week high on September 8, 2026, driven by a series of clinical developments and important regulatory milestones. Pharvaris N.V. (PHVS) Pharvaris…NasdaqATRC, BLSM, FTH, PHVS